Iqvia (NYSE:IQV) was upgraded by analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a report released on Friday, MarketBeat.com reports. The firm presently has a $150.00 target price on the medical research company’s stock, up from their prior target price of $136.00. Jefferies Financial Group’s price target suggests a potential upside of 17.93% from the company’s current price. Jefferies Financial Group also issued estimates for Iqvia’s Q4 2018 earnings at $1.37 EPS and FY2018 earnings at $5.14 EPS.
IQV has been the topic of several other reports. Morgan Stanley boosted their target price on shares of Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, December 3rd. Goldman Sachs Group raised shares of Iqvia from a “buy” rating to a “conviction-buy” rating in a research note on Friday, January 11th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $142.00 target price on the stock in a research note on Tuesday, October 23rd. Piper Jaffray Companies boosted their target price on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a research note on Tuesday, October 23rd. Finally, Royal Bank of Canada boosted their target price on shares of Iqvia to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, October 23rd. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $139.47.
Shares of NYSE:IQV opened at $127.19 on Friday. Iqvia has a one year low of $91.57 and a one year high of $135.48. The firm has a market cap of $24.82 billion, a PE ratio of 29.17, a P/E/G ratio of 1.58 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09.
In related news, CFO Michael R. Mcdonnell sold 9,500 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $128.35, for a total value of $1,219,325.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total transaction of $442,118,987.40. The disclosure for this sale can be found here. Insiders sold 6,747,433 shares of company stock valued at $834,836,396 in the last three months. Company insiders own 6.00% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Iqvia by 588.8% during the third quarter. FMR LLC now owns 2,989,843 shares of the medical research company’s stock worth $387,902,000 after buying an additional 2,555,776 shares in the last quarter. Steadfast Capital Management LP increased its holdings in shares of Iqvia by 218.4% during the third quarter. Steadfast Capital Management LP now owns 2,796,870 shares of the medical research company’s stock worth $362,866,000 after buying an additional 1,918,336 shares in the last quarter. Third Point LLC acquired a new stake in shares of Iqvia during the third quarter worth approximately $194,610,000. USS Investment Management Ltd increased its holdings in shares of Iqvia by 173.0% during the fourth quarter. USS Investment Management Ltd now owns 1,820,200 shares of the medical research company’s stock worth $211,498,000 after buying an additional 1,153,500 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Iqvia by 51.8% during the third quarter. Capital Research Global Investors now owns 3,055,858 shares of the medical research company’s stock worth $396,467,000 after buying an additional 1,042,431 shares in the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Featured Story: Fiduciary
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.